Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab Deruxtecan vs Docetaxel in mCRPC
NCT06925737Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival at 36 months and Radiographic Progression Free Survival at 36 months. Started May 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06925737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925737.